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Abstract
Background: Multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB) are global health problems.
We sought to determine the characteristics, prevalence, and relative frequency of transmission of MDR and XDR TB in
Shanghai, one of the largest cities in Asia.
Methods: TB is diagnosed in district TB hospitals in Shanghai, China. Drug susceptibility testing for first-line drugs was
performed for all culture positive TB cases, and tests for second-line drugs were performed for MDR cases. VNTR-7 and VNTR-
16 were used to genotype the strains, and prior treatment history and treatment outcomes were determined for each patient.
Results: There were 4,379 culture positive TB cases diagnosed with drug susceptibility test results available during March
2004 through November 2007. 247 (5.6%) were infected with a MDR strain of M. tuberculosis and 11 (6.3%) of the 175 MDR
patients whose isolate was tested for susceptibility to second-line drugs, were XDR. More than half of the patients with MDR
and XDR were newly diagnosed and had no prior history of TB treatment. Nearly 57% of the patients with MDR were
successfully treated.
Discussion: Transmission of MDR and XDR strains is a serious problem in Shanghai. While a history of prior anti-TB
treatment indicates which individuals may have acquired MDR or XDR TB, it does not accurately predict which TB patients
have disease caused by transmission of MDR and XDR strains. Therefore, universal drug susceptibility testing is
recommended for new and retreatment TB cases.
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Introduction
Since 1994, nearly 90 countries and regions worldwide have
reported one or more cases of multidrug-resistant (MDR)
tuberculosis (TB) [1]. MDR TB is defined as TB caused by a
strain of M. tuberculosis that is resistant to at least isoniazid and
rifampin, two of the most important first-line drugs used to treat
the disease [2]. China had approximately 140,000 MDR TB cases
in 2004, or one third of the estimated global burden of MDR TB
[1]. In some provinces of China, the prevalence of MDR TB
among new cases and previously treated cases was above 10% and
30%, respectively [3]. However, the number and percentage of
MDR TB cases in Shanghai, one of the largest cities in Asia, has
not previously been reported.
In 2006, multiple cases of extensively drug-resistant (XDR) TB
were reported in South Africa, raising concerns that XDR strains
of M. tuberculosis are prevalent in other populations. Many of the
cases reported from South Africa occurred among HIV-infected
persons and there was a high case fatality rate [4]. By November
2007, 41 countries had reported XDR TB cases [5]. The mortality
rate of XDR TB patients varies in different countries and depends
on the study population and their HIV status [4,6–8]. More than
fifty percent of HIV-uninfected XDR TB patients have been
successfully treated in South Korea [6], but the duration of
treatment is prolonged and the financial burden is high [7]. XDR
TB has not previously been formally reported in mainland China,
but given the high prevalence of TB nationwide, the large number
of MDR TB cases in the country, and the long-time use of second
line anti-TB drugs and fluroquinolones, the existence of XDR TB
in China seems inevitable.
We performed a retrospective study to determine the number
and percentage of TB patients in Shanghai with MDR and XDR
TB, and to determine whether there is transmission of MDR and
XDR strains of M. tuberculosis in Shanghai.
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Study population
We performed a retrospective cohort study using the existing
data and specimens at the Shanghai Municipal Center for Disease
Control and Prevention (Shanghai CDC), from TB patients who
were diagnosed in Shanghai during March 2004 through
November 2007. Since 1995 in Shanghai, all suspected pulmonary
TB cases detected in general hospitals or community health
centers were referred to a specialized TB hospital or TB clinic for
further diagnostic tests, including sputum smear examinations,
culture and chest radiography. There were 31 designated district
TB hospitals in Shanghai; all of the pretreatment positive cultures
from patients in each hospital were sent to the Tuberculosis
Reference Laboratory (TRL) at Shanghai CDC for drug
susceptibility testing and species identification. Shanghai CDC
also collected data on the social and demographic characteristics,
treatment history, clinical characteristics, drug-susceptibility test
results, and clinical outcomes of each patient. All of the
investigation protocols in this study were approved by ethics
committee of Fudan University. Since this was a retrospective
study and all patients’ information was routinely collected by
Shanghai CDC for analysis and reports to the government,
consent was not obtained from the patients during 2004 through
2006. We started a research project in 2007, and informed consent
has been obtained from all patients since then for the information
to be used in scientific studies.
Drug susceptibility testing (DST)
TRL at Shanghai CDC participated in the World Health
Organization/International Union against Tuberculosis and Lung
Disease Global Project on Anti-Tuberculosis Drug Resistance
Surveillance [2]. Species identification of mycobacteria was per-
formed by conventional biochemical and PCR tests [9]. The first-line
drug susceptibility testing was routinely performed by the absolute
concentrationorproportion methodsonisolates ofM.tuberculosis[10].
In the present study, we restricted our analysis to those patients
whose first-line drug susceptibility tests were performed by the
proportion method. The following drug concentrations were used:
isoniazid (0.2 mg/ml), rifampin (40.0 mg/ml), streptomycin
(4.0 mg/ml) and ethambutol (2.0 mg/ml). For any isolates that
were MDR, we also used the WHO Guidelines for drug
susceptibility testing for second-line anti-tuberculosis drugs for
DOTS plus [11]. We chose five second-line drugs widely used for
MDR TB treatment in Shanghai and performed drug suscepti-
bility tests using the following concentrations: ofloxacin (2.0 mg/
ml), kanamycin (30.0 mg/ml), capreomycin (40.0 mg/ml), amika-
cin (40.0 mg/ml) and 4-aminosalicylic acid (1.0 mg/ml). To ensure
the consistency and reliability of results, all second-line drug
susceptibility testing was performed by a senior technician who
had completed and passed the WHO’s quality control evaluation.
All drugs were obtained from Sigma Life Science Company
(USA).
Definitions
MDR TB was defined as tuberculosis disease caused by a strain
of M. tuberculosis that was resistant to at least isoniazid and
rifampin. XDR was defined as TB with resistance to at least
isoniazid, rifampin, a fluoroquinolone (e.g. mofloxacin, ofloxacin,
levofloxacin, sparfloxacin, gatifloxacin, ciprofloxacin) and one of
three injectable second-line drugs (capreomycin, kanamycin, and
amikacin) [12]. Pre-XDR was defined as disease caused by a strain
resistant to isoniazid and rifampin and either a fluoroquinolone or
a second-line injectable drug, but not both [13]. In the present
study, we use the terms simple MDR, which refers to isolates that
are resistant to just isoniazid and rifampin but not pre-XDR TB
and XDR TB.
New cases were defined as TB patients who denied having had
any prior anti-TB treatment or who received anti-TB treatment
for ,30 days. Previously treated cases were TB patients who
reported having been treated for tuberculosis for at least 30 days or
who had documented evidence of prior treatment in the case
report form or surveillance database. Acquired drug resistance was
defined as the isolation of drug-resistant M. tuberculosis from a
patient who has been treated for tuberculosis for one month or
longer [14]. Primary drug resistance is the isolation of a drug-
resistant strain from a patient without a history of previous
treatment [14].
Migrants were defined as individuals from other areas of China
who moved to Shanghai. Residents were defined as persons with a
registered permanent residence in Shanghai.
Genotyping method
We used the VNTR-7 and VNTR-16 methods to genotype the
189 clinical isolates of M. tuberculosis, following the protocol
described by Zhang [15]. First, VNTR-7 was performed in all
isolates and the isolates with identical VNTR-7 genotyping pattern
werefurther differentiated by VNTR-16. We also used the deletion-
targetedMultiplexPCR(DTM-PCR)method toidentifytheBeijing
genotype strains [16]. Primers were synthesized by Invitrogen Bio
Co. (China) and polymerase chain reaction (PCR) mixtures were
prepared using the 26Taq MasterMix (Tiangen Co., China). PCR
products were separated using an agarose gel and were analyzed by
Quantity 1 gel imaging system (Bio-Rad Co., USA).
Clinical treatment
There is presently no standard treatment strategy, such as
DOTS-Plus, to guide the therapy of MDR-TB patients in
Shanghai. Individualized therapies were given to MDR TB
patients based on the patient’s physical and financial situation, the
strains’ drug-susceptibility patterns and the clinicians’ experience.
The following drugs were used, in different combinations: two
injectable second-line drugs, including capreomycin and amikacin;
fluoroquinolones, including ofloxacin, levofloxacin, gatifloxacin,
moxifloxacin and ciprofloxacin; a modified form of isoniazid,
called prothionamide; two modified forms of rifampicin, called
rifapentine and rifabutin; and 4-aminosalicylic acid.
Statistical analysis
We used the chi-square test of proportions to identify significant
differences between two or more groups of patients. A p
value,0.05 was considered statistically significant. Odd ratios
(ORs) and 95% confidence intervals (CI) were calculated to
measure the association between patient characteristics and the
outcome of interest. All analyses were performed using Stata
statistical software (version 8.0SE, Stata Corporation, College
Station, Texas, USA).
Results
MDR TB
From March 2004 through November 2007, there were 19,722
newly registered pulmonary tuberculosis patients in 31 designated
district tuberculosis hospitals in Shanghai. Of these, 6,200 (31.4%)
patients were culture positive for M. tuberculosis. We excluded 1,537
culture-positive TB patients who were diagnosed during May 2005
through February 2006 because the drug susceptibility testing of
their isolates was performed using the absolute concentration
MDR/XDR TB Transmission
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treatment history of the patients who were included and excluded
from the study population and found no significant differences
(data not shown). Of the remaining 4,663 TB patients, we further
excluded 95 (2.0%) patients whose isolate lacked a drug
susceptibility test result and 189 (4.1%) patients who were infected
with Mycobacterium other than M. tuberculosis (MOTT). The
remaining 4,379 patients with culture-confirmed M. tuberculosis and
their drug susceptibility test results were used for analysis. Among
them, 247 (5.6%, 247/4,379) TB patients had disease caused by a
MDR strain of M. tuberculosis (figure 1).
XDR TB
To determine the number and percentage of the MDR TB
patients that were infected with an XDR strain of M. tuberculosis,
we performed drug susceptibility testing for five second-line drugs
on the isolates of the MDR TB patients in the study population.
However, the isolates from 72 of the 247 MDR TB patients were
missing or could not be recovered from the storage; isolates from
175 (70.9%) MDR TB patients were tested for susceptibility to a
second-line drug. We compared the clinical characteristics of the
TB patients whose isolate was tested for susceptibility to second-
line drugs and the TB patients whose isolates were missing or
Figure 1. Study population of cases of drug resistant tuberculosis in Shanghai, March, 2004–November, 2007. TB=tuberculosis.
MDR=multidrug-resistant. MOTT=Mycobacteria other than tuberculosis.
doi:10.1371/journal.pone.0004370.g001
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differences between the two groups (data not shown). Among the
175 MDR patients, 109 patients (62.3%) were infected with a
strain of M. tuberculosis that was simple MDR, 55 patients (31.4%)
were infected with a strain that was pre-XDR, and 11 (6.3%)
patients were infected with an XDR strain of M. tuberculosis.
Characteristics of MDR, pre-XDR and XDR TB patients
We compared the patient characteristics associated with MDR,
pre-XDR and XDR TB, such as age, sex, treatment history and
status (resident versus migrant) (table 1). Most MDR patients were
30 to 59 years old, and XDR TB was more likely to occur in
persons 45 to 59 years than among person who were younger or
older (p=0.0067). Sixty percent of the patients with MDR and
54.5% of the patients with XDR were new cases.
Treatment outcomes of MDR patients
Fifty-six percent of the patients with MDR TB and 9.1% of the
patients with XDR TB were successfully treated. The cure rate in
simple MDR TB, pre-XDR TB and XDR TB patients decreased
and the mortality increased as the drug resistance increased
(table 2). The cure rate of MDR TB in new cases was higher than
the cure rate of MDR TB among previously treated cases (table 3).
Genotypes of M. tuberculosis
We genotyped one isolate from each of 175 MDR TB patients.
87.3% (165/189) of the MDR isolates and 90.9% (10/11) of the
XDR isolates were Beijing genotype strains. Patients infected with
M. tuberculosis strains that had the same VNTR pattern were
assumed to be part of a chain of transmission [15,17]. Four clusters
were identified, each with 2 different patients. To determine
whether the cluster of two patients represented a chain of
transmission of M. tuberculosis, we sought epidemiological links
between them. Patients in two clusters lived in different districts,
but patients in the other two clusters lived in the same district and
had been diagnosed and treated in the same hospital and no
additional epidemiological links between them were detected.
None of the isolates with XDR were in a genotype cluster.
Discussion
The present study showed that 5.6% of the tuberculosis patients
in Shanghai were infected with a strain of M. tuberculosis that was
MDR. Furthermore, 6.3% of the MDR TB patients were XDR.
Nearly 55% (6/11) of the XDR TB patients were new cases,
suggesting there is transmission of highly drug-resistant strains of
M. tuberculosis in Shanghai.
Since second-line drugs have been used in Shanghai for several
decades and there is no standard treatment strategy for patients
with MDR and pre-XDR strains, there was concern that the
prevalence of XDR TB in Shanghai would be higher. Based on
our study using specimens from the 31 designated district
tuberculosis hospitals, we report that XDR TB occurs in
Shanghai, albeit currently with a relatively low prevalence during
the study period.
After XDR TB became a public concern during 2006, many
countries retested their stored isolates and XDR strains were
reported in 41 countries [5]. The reported percentage of XDR TB
patients among the MDR TB patients varies between countries,
from 3% in the United States to 19% in Latvia [18], and the
average rate is about 10% [19]. The percentage of MDR and
XDR TB patients that are detected depends on the study design,
the sampling frame and the study population. For example,
hospital based studies will likely include a greater proportion of
seriously ill TB patients, including patients who are undergoing
Table 1. Characteristics of tuberculosis patients by drug resistance group, Shanghai, March 2004–November 2007.
Characteristic All MDR Simple MDR Pre-XDR XDR x
2 P
n=175 (%) n=109 (%) n=55 (%) n=11 (%)
Age (years) 16.182 0.040
15–29 35 (20.0) 24 (22.0) 11 (20.0) 0 (0.0)
30–44 53 (30.3) 37 (33.9) 13 (23.6) 3 (27.3)
45–59 57 (32.6) 26 (23.9) 23 (41.8) 8 (72.7)
60–74 20 (11.4) 14 (12.8) 6 (10.9) 0 (0)
$75 10 (5.7) 8 (7.4) 2 (3.6) 0 (0)
Sex 2.772 0.250
Male 132 (75.4) 84 (77.1) 38 (69.1) 10 (90.9)
Female 43 (24.6) 25 (22.9) 17 (30.9) 1 (9.1)
Treatment history 1.314 0.519
New 105 (60.0) 69 (63.3) 30 (54.5) 6 (54.5)
Retreatment 70 (40.0) 40 (36.7) 25 (45.5) 5 (45.5)
Status 0.480 0.787
Resident 112 (64.0) 70 (64.2) 34 (61.8) 8 (72.7)
Migrant 63 (36.0) 39 (35.8) 21 (38.2) 3 (27.3)
MDR=resistance to at least isoniazid and rifampin.
Simple MDR=resistance to only isoniazid and rifampin.
Pre-XDR=Pre-extensively drug resistant; the strain is resistant to isoniazid, rifampin, and a fluoroquinolone or three of the second-line drugs (capreomycin, amikacin,
kanamycin).
XDR=extensively drug resistant; the strain is resistant to isoniazid, rifampin and a fluoroquinolone and any of three of the second-line drugs (capreomycin, amikacin,
kanamycin).
doi:10.1371/journal.pone.0004370.t001
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provide a lower estimate of the percentage of total TB patients
who are infected with an MDR or XDR strain of M. tuberculosis.
More than half of the infections with MDR and XDR strains of
M. tuberculosis in our study occurred among new TB cases, a
finding which suggests that the transmission of MDR and XDR
strains of M. tuberculosis is a serious problem in Shanghai. The
prevalence of primary drug resistance may actually be higher than
our estimate. Transmission of drug-resistant M. tuberculosis can
cause primary drug resistance among individuals with no prior
history of TB, as well as among individuals with a history of prior
TB treatment. Previously, we showed that 84% of retreated TB
patients with drug-resistant disease actually had primary drug
resistance, not acquired drug resistance [20]. Andrews, et al. also
reported that most of the MDR/XDR cases in South Africa were
primary drug resistance [21]. In addition, a recent meta-analysis
showed that primary drug resistance was associated with poor
treatment outcomes if treatment regimens were not based on drug
susceptibility test results [22]. In communities with a high rate of
primary drug resistance, approaches which assign treatment
regimens based solely on the patient’s history of prior treatment
may amplify drug resistance [22]. MDR and XDR patients in
China are often poor and cannot afford the second-line anti-TB
drugs, making it difficult to achieve treatment success. MDR and
XDR patients without adequate treatment regimens will continue
to be sources of infection, causing more MDR and XDR infections
Table 2. Treatment outcome of tuberculosis patients with MDR TB, pre-XDR TB, and XDR TB.
Simple MDR Pre-XDR XDR Total
n=109 (%) n=55 (%) n=11 (%) n=175 (%)
Cured, bacteriological confirmed 62 (56.9) 29 (52.7) 1 (9.1) 92 (52.6)
Completed treatment regimen 3 (2.8) 2 (3.6) 0 (0.0) 6 (3.4)
Died during TB treatment 6 (5.5) 5 (9.1) 1 (9.1) 12 (6.9)
Still on treatment 30 (27.5) 14 (25.5) 8 (72.7) 51 (29.1)
Lost to follow up 1 (0.9) 1 (1.8) 1 (9.1) 3 (1.7)
Moved/transferred 7 (6.4) 4 (7.3) 0 (0) 11 (6.3)
MDR=resistance to at least isoniazid and rifampin.
Simple MDR=resistance to only isoniazid and rifampin.
Pre-XDR=Pre-extensively drug resistant; the strain is resistant to isoniazid, rifampin, and a fluoroquinolone or any one of three second-line drugs (capreomycin,
amikacin, kanamycin).
XDR=extensively drug resistant; the strain is resistant to isoniazid, rifampin and a fluoroquinolone and any one of three second-line drugs (capreomycin, amikacin,
kanamycin).
doi:10.1371/journal.pone.0004370.t002
Table 3. Treatment outcomes among tuberculosis (TB) patients with simple MDR TB, pre-XDR TB and XDR TB, stratified by new
cases versus previously treated cases.
Treatment success No treatment success Odds ratio (OR) 95% CI P
N=96 (54.9%) N=79 (45.1%)
XDR
New 0 (0.0) 6 (3.4)
Retreatment 1 (0.6) 4 (2.3) - - 0.2506
Pre-XDR
New 23 (13.1) 9 (5.1) 1.00
Retreatment 8 (4.6) 15 (8.6) 4.79 (1.32, 17.85) 0.0062
Simple MDR
New 47 (26.9) 19 (10.9) 1.00
Retreatment 17 (9.7) 26 (14.9) 3.78 (1.56, 9.24) 0.0010
Total
New 70 (40.0) 34 (19.4) 1.00
Retreatment 26 (14.9) 45 (25.7) 3.56 (1.80, 7.06) 0.0001
OR=odds ratio.
CI=confidence interval.
MDR=resistance to at least isoniazid and rifampin.
Simple MDR=resistance to only isoniazid and rifampin.
Pre-XDR=Pre-extensively drug resistant; the strain is resistant to isoniazid, rifampin, and a fluoroquinolone or any one of three second-line drugs (capreomycin,
amikacin, kanamycin).
XDR=extensively drug resistant; the strain is resistant to isoniazid, rifampin and a fluoroquinolone and any one of three second-line drugs (capreomycin, amikacin,
kanamycin).
doi:10.1371/journal.pone.0004370.t003
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including rapid drug susceptibility testing techniques, are urgently
needed.
To identify chains of transmission of M. tuberculosis is arduous
work, requiring a prospective population-based cohort study
design, high case detection rates and additional epidemiological
information. In the present study, four clusters of patients with
identical genotype patterns were identified among 175 MDR TB
patients, but epidemiological links between them were difficult to
establish. Another limitation of the present study is that isolates of
some TB patients were not available for drug susceptibility testing
and genotyping, or their drug susceptibility test was performed
with the absolute concentration method. However, this is a
retrospective study and we were able to investigate only some of
the MDR TB patients. Therefore, the recent transmission of M.
tuberculosis based on genotyping results is likely underestimated.
Overall, the treatment outcomes of MDR TB patients have
been less favorable than the treatment outcomes of TB patients
whose disease is caused by a pan-susceptible strain, a mono-
resistant, or a poly-resistant strain of M. tuberculosis [23,24]. Some
MDR TB patients can be successfully treated, even as outpatients
[25]. The XDR TB epidemic in Tugela Ferry, South Africa,
which had a high prevalence of co-infection with HIV and a high
case fatality ratio, led some to label XDR TB an ‘‘untreatable’’
disease. However, a study from South Korea reported that more
than fifty percent of HIV-uninfected XDR TB patients were
successfully treated [6], as were 60.4% of XDR TB patients in
Peru and 41.2% of XDR TB patients completed therapy in
California [13,26].
Our study showed that the cure rate is higher among new TB
cases than among previously treated TB cases, whether they were
MDR or pre-XDR patients. A previous study reported that TB
patients with primary drug resistant tuberculosis had better
treatment outcomes than TB patients with acquired drug resistant
TB [27], although this is not always the case. The concept of pre-
XDR TB is important for public health purposes, to allow the
community to assess how many XDR TB cases are likely to
emerge and to make concerted efforts to treat the individuals
whose disease is caused by a pre-XDR strain of M. tuberculosis.
Theoretically, it is difficult to gain resistance to two kinds of drugs
simultaneously. In our study, 78% (43/55) of the pre-XDR isolates
were resistant to a fluoroquinolone and were, therefore, one
mutation away from becoming XDR. Fluoroquinolones have been
used extensively in Shanghai during the past twenty years to treat
drug-resistant TB patients and retreatment patients.
In summary, 5.6% of the TB cases in Shanghai were infected
with a MDR strain of M. tuberculosis, and further drug susceptibility
testing showed that 6.3% of the patients whose isolate was MDR
were actually XDR. More than half of the patients with MDR and
XDR were new cases, suggesting that the transmission of drug-
resistant strains in Shanghai is a serious problem. Currently, the
rapid diagnosis and treatment of persons with TB, particularly any
form of drug-resistant TB, are high priority public health
interventions. Universal drug susceptibility testing is recommend-
ed for new and retreatment TB cases.
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